



## **Adelene Q. Perkins Named "Best Executive" at Annual Stevie(R) Awards Ceremony**

CAMBRIDGE, Mass., Nov. 16, 2009 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today announced that Adelene Q. Perkins, president and chief business officer, was named the 2009 "Best Executive: Non-Services Business" in the 6th Annual Stevie Awards for Women in Business, presented at the Annual Award Dinner and Ceremony held on November 13, 2009 in New York City.

Ms. Perkins was selected from more than 1,100 nominees across several categories at this international award competition. A board of 50 judges and advisors from around the world selected the Stevie Award Winners from among the finalists. Ms. Perkins was recognized as "Best Executive" for non-service organizations with up to 2,500 employees. In 2008, Ms. Perkins was a finalist for the "Lifetime Achievement Award" in the Annual Stevie Awards for Women.

"I am humbled to receive this recognition alongside so many respected and impactful business leaders," said Ms. Perkins. "I accept the award on behalf of all of Infinity's Citizen-Owners. Without such an exceptional team, and the support of my family, this award would not have been possible; I am grateful for all of them."

Ms. Perkins has more than 25 years of general management experience in the healthcare, pharmaceutical, and biotechnology industries. She joined Infinity early in its history, and has been an integral figure in establishing Infinity's strategic plan and leading the company through significant growth. She has played a central role in structuring and executing all of Infinity's strategic alliances, including its global strategic alliance with Purdue Pharmaceutical Products L.P. and Mundipharma International Corporation Limited entered into in November 2008. Ms. Perkins also maintains executive responsibility for all of Infinity's business functions, including corporate and product development, commercial affairs, corporate communications, finance, human resources, and legal affairs.

"Adelene is an exceptional leader and extraordinary human being," said Steven H. Holtzman, Infinity's founder, chair and chief executive officer. "Her passion for and dedication to achieving Infinity's mission to bring meaningful new medicines to patients with cancer is an inspiration to our Citizen-Owners. It is a genuine pleasure, and even more of a privilege, to work shoulder-to-shoulder with her to advance the growth and sustainability of Infinity. "

Ms. Perkins joined Infinity in 2002 after helping to build TransForm Pharmaceuticals, where she served as vice president of corporate and business development. She previously held senior leadership positions at Genetics Institute and Bain and Company. Ms. Perkins holds an M.B.A. from Harvard Business School and a B.S. in Chemical Engineering from Villanova University. She and her husband, Roland Perkins, have four children.

### About Stevie(R) Awards

Stevie Awards are conferred in four programs: The American Business Awards, The International Business Awards, The Stevie Awards for Women in Business, and The Stevie Awards for Sales & Customer Service. Honoring organizations of all types and sizes and the people behind them, the Stevies recognize outstanding performances in the workplace worldwide. Learn more about The Stevie Awards at [www.stevieawards.com](http://www.stevieawards.com).

Sponsors of the 6th Annual Stevie Awards for Women in Business include the Business TalkRadio Network, Covario, Inc., and KeyBank. Localization partner of the 2009 Stevie Awards is Lionbridge.

### About Infinity Pharmaceuticals, Inc.

Infinity is an innovative cancer drug discovery and development company seeking to discover, develop, and deliver to patients best-in-class medicines for the treatment of cancer and related conditions. Infinity combines proven scientific expertise with a passion for developing novel small molecule drugs that target emerging cancer pathways. Infinity's two most advanced programs in Hsp90 chaperone inhibition and Hedgehog signaling pathway inhibition are evidence of its innovative approach to oncology drug discovery and development. For more information on Infinity, please refer to the company's website at <http://www.infi.com>.

CONTACT: Infinity Pharmaceuticals, Inc.  
Monique Allaire

617-453-1105  
Monique.Allaire@infi.com  
<http://www.infi.com>

(C) Copyright 2009 GlobeNewswire, Inc. All rights reserved.